Company Overview and News
WallStars exhibit positive broker target price upsides. Energy firms with over 2.1% dividend yield made a list of 84 WallStars.
RDS.B RDS.A SNP GLOP VLP RDSB VLO RDSA MPC SNP SHLX CVX RYDBF GPP RYDAF CEO SNMP
2018-10-11 seekingalpha - 1
Energy equities with over .05% Broker Target Upsides showed midstream firms top on the list, Sanchez for price gains and American Midstream for dividend yield, as of 10/8/18.
NGL AMID SNP MMLP SMLP BPL CCLP ETP SNP USAC GPP CVRR SNMP
2018-09-17 zacks - 1
China Petroleum & Chemical Corporation (SNP - Free Report) , widely known as Sinopec, recently joined a group to build an oil sands refinery in Alberta. Apart from Sinopec, the group consists of an Albertan indigenous group, China State Construction Engineering Corp. and Alberta management company Teedrum. The partnership will be known as SinoCan Global, which has selected Stantec Inc. (STN - Free Report) for providing consulting services concerning the project’s regulatory review and permitting process.
SNP STN SNP STN
2018-09-07 seekingalpha - 1
Energy equities with over .72% Broker Target Upsides showed midstream firms tops on the list, Sanchez, for price upside and American Midstream for net gains, and yield as of 9/6/18.
NGL AMID SNP MMLP SMLP BPL CCLP ETP SNP USAC GPP CVRR ENBL SNMP
China Petroleum and Chemical Corporation (SNP - Free Report) , also known as Sinopec, reported net profit of 42.4 billion yuan ($6.65 billion) or 0.350 yuan per share in the first half of 2018. The bottom line surpassed the year-ago profit level of 27.9 billion yuan ($4.06 billion) or 0.231 yuan. The improvement can be attributed to outstanding performance in the Chemicals segment. Moreover, increase in natural gas volumes also contributed to growth.
HLX TCP SNP SNP
2018-08-07 seekingalpha - 2
Several crude oil-to-chemical (COTC) projects being planned or started in Asia and Saudi Arabia threaten to reshape the global petrochemical industry in the coming years. COTCs configure a refinery to produce maximum chemicals instead of traditional transportation fuels. Since refinery processing capacity is approximately 10 times higher than the current world-scale petrochemical plants, COTC in effect raises petrochemical production to an unprecedented refinery scale.
SNP SNP MDR PTR CEO
The Papua New Guinea (PNG) liquefied natural gas (“LNG”) project, operated by Exxon Mobil Corporation (XOM - Free Report) , recently struck a supply deal with PetroChina Company Limited (PTR - Free Report) .
COP OISHF SNP OISHY XOM SNP OSH
Chevron Corporation (CVX - Free Report) is planning to leave the Makassar Strait gas block in Indonesia to shift its focus on more profitable opportunities in the area, per reports. The block is part of the Indonesia Deepwater Development (IDD) project, which is one of the biggest natural gas projects in the country.
SNP RDS.B RDS.A SNP CVX RYDBF RDSB RDSA RYDAF SAM
A prudent investor keeps adding well-performing stocks when the time is right and sells the risky ones. Strong fundamentals and favorable price performance indicate a stock’s bullish run. BP plc (BP - Free Report) is among the leading integrated energy players in the world. The stock has performed well in the past six months and has the potential to sustain the momentum in the near term. Therefore, if you haven’t taken advantage of the share price appreciation yet, it’s time you add the stock to your portfolio.
SNP SNP CVRR OXY
Equinor ASA (EQNR - Free Report) intends to acquire 100% of the shares in Danish energy trading company, Danske Commodities (DC). Per the agreement, Equinor will pay EUR 400 million in smaller contingent payments, subject to Danske’s performance over the next couple of years. About Danske Commodities Founded in 2004, Danske Commodities is based in Aarhus, Denmark, with a workforce of 284 employees.
SNP SNP CVRR OXY
Chicago, IL – June 12, 2018 – Zacks Equity Research highlights Six Flags Entertainment Corp (SIX - Free Report) as the Bull of the Day, Thomson Reuters (TRI - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Toyota Motor Corporation (TM - Free Report) , China Petroleum & Chemical Corporation (SNP - Free Report) and Merck & Co., Inc. (MRK - Free Report) .
SIX SNP TM SNP 7203 TRI TYT WTW LYV TOYOF CVA VSTO
After small-caps took charge of the bull run through February to May, mega caps returned to the forefront in June. This is especially true as the blue-chip Dow Jones index climbed 3.7% to start June, outpacing the gains of 2.7% for the S&P 500 and 2.4% for the Russell 2000. Notably, the Dow Jones surged 2.8% last week, its biggest weekly gain since March. Improving domestic and international fundamentals, a firming dollar and compelling valuation led to the outperformance.
WFC WFCNP TM SNP TYT TOYOF SNP 7203
Chevron Corporation’s (CVX - Free Report) South African asset divestment recently witnessed a new turn of events, as competition among the bidders became intense. China Petroleum & Chemical Corporation or Sinopec (SNP - Free Report) and Switzerland-based Glencore Plc (GLNCY - Free Report) were in the race to acquire the assets.
APC COF-P SNP COF COF-D COF-C COF-F SNP CVX OXY AEUA GLNCY
Per Forbes Global 2000’s list of the biggest and most powerful public companies, Royal Dutch Shell plc (RDS.A - Free Report) has climbed to the top spot pushing aside last year's leader Exxon Mobil Corporation (XOM - Free Report) . Shell holds rank 11 among all companies on the list, while it was positioned at rank 20 in 2017. The improvement in rank is mainly attributable to higher sales due to rising commodity prices.
RDS.B RDS.A 500325 XOM SNP RELIANCE RDSB RDSA SNP CVX RIGD RYDBF RYDAF RLNIY
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to LSE:SNP / CHINA PETROLEUM & CHEMICAL CORP on message board site Silicon Investor.